I am a specialist in pulmonary and critical care medicine with expertise in lung diseases that result from immune-suppressing cancer treatments. I provide clinical consultation for hospitalized patients who are immunocompromised and develop respiratory complications of cancer and related therapies. My specific interests include pulmonary complications of hematopoietic stem cell transplantation and the use of bronchoscopy as a diagnostic tool in this population.
Lung injury following hematopoietic cell transplantation can be very serious, especially in the acute setting. The causes of lung injury are not always clear, which presents challenges to their management. My research focuses on how the microorganisms that normally inhabit the body contribute to infectious and inflammatory lung diseases following transplantation. My hope is that improved understanding of risk factors and mechanisms of transplant-related lung injury will drive advances in diagnosis, treatment, and prevention.
- Clinical Expertise: Pulmonary Disease in the Immunocompromised Patient; Pulmonary Complications of Hematopoietic Stem Cell Transplantation
- Languages Spoken: English
- Education: MD, New York University School of Medicine; MSc, London School of Hygiene and Tropical Medicine (UK)
- Residencies: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowships: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Board Certifications: Internal Medicine; Pulmonary Disease; Critical Care Medicine
Diagnostic bronchoscopy in solid-organ and hematopoietic stem cell transplantation, Harris B, Lowy FD, Stover DE, Arcasoy SM. Annals of the American Thoracic Society, 2013-10(1):39-49.
The association of systemic microvascular changes with lung function and lung density: a cross-sectional study. Harris B, Ahmed F, Klein R, Jerosch-Herold M, Hoffman EA, Jacobs D, Klein B, Wong T, Cotch MF, Barr RG. PLoS ONE 2012:7(12): doi:10.1371/journal.pone.0050224.
Ventricular assist device-related infections, Gordon RJ, Quagliarello (Harris) B, Lowy FD, Lancet Infectious Diseases 2006: 6(7); 426-37.
Staphylococcus aureus colonization and the risk of infection in critically Ill patients. Keene A, Vavagiakis P, Lee MH, Finnerty KA, Nicholls D, Cespedes C, Quagliarello (Harris) B, Chiasson MA, Chong DH, Lowy FD. Infection Control and Hospital Epidemiology 2005: 26 (7): 622-627.
Molecular epidemiologic analysis of two Staphylococcus aureus clonal types colonizing AIDS patients. Gordon R, Quagliarello (Harris) B, Cespedes C, Chung C, de Lencastre H, Vavagiakis P, Miller M, Zeller B, and Lowy FD. A Clinical Infectious Diseases 2005: 40 (7): 1028-36.
Strains of Staphylococcus aureus obtained from drug-use networks are closely linked. Quagliarello (Harris) B, Cespedes C, Miller M, Toro A, Vavagiakis, Klein RS, Lowy FD. Clinical Infectious Diseases 2002: 35; 671-677.
Factors associated with carriage of penicillin-resistant Streptococcus pneumoniae among Vietnamese children: a rural-urban divide. Quagliarello (Harris) B, Parry CM, Hien TT, Farrar J. Journal of Health, Population and Nutrition 2003 Dec; 21 (4): 316-24.
Differences between Staphylococcus aureus isolates from medical and nonmedical hospital personnel. Cespedes C, Miller M, Quagliarello (Harris) B, Vavagiakis P, Klein RS, Lowy FD. Journal of Clinical Microbiology 2002: 40 (7); 2594-2597.
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more